Dermapharm Holding SEDMPHF 83 EV-to-FCF is 12.84 as of Jun. 30, 2026, which is 22% below its 10-year median of 16.51. GuruFocus rates DMPHF with a GF Score™ of 83/100 and a GF Value™ of $44.29 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 558 Drug Manufacturers companies, Dermapharm Holding SE ranks better than 66.31% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Dermapharm Holding SE's Enterprise Value is $3,602 Mil.
Dermapharm Holding SE's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $280 Mil. Therefore, Dermapharm Holding SE's EV-to-FCF for today is 12.84.
The historical rank and industry rank for Dermapharm Holding SE's EV-to-FCF or its related term are showing as below:
DMPHF'
s EV-to-FCF Range Over the Past 10 Years
Min: 6.17 Med: 16.51 Max: 139.75
Current: 13.13
During the past 13 years, the highest EV-to-FCF of Dermapharm Holding SE was 139.75. The lowest was 6.17. And the median was 16.51.
DMPHF's EV-to-FCF is ranked better than 66.31% of 558
companies
in the Drug Manufacturers industry
Industry Median: 20.045
vs DMPHF: 13.13
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Dermapharm Holding SE (OTCPK:DMPHF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Dermapharm Holding SE's PE Ratio (TTM) for today is calculated as:
Dermapharm Holding SE's share price for today is $53.00.
Dermapharm Holding SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.121.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermapharm Holding SE EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Dermapharm Holding SE's EV-to-FCF falls into.
Dermapharm Holding SE's current Enterprise Value is $3,602 Mil.
Dermapharm Holding SE's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $280 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dermapharm Holding SE (DMPHF) has a EV-to-FCF of 12.84 as of Jun. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Dermapharm Holding SE and its competitors. This is 22% below median its historical median of 16.51. Over the past decade, Dermapharm Holding SE's EV-to-FCF has ranged from 6.17 to 139.75. According to the industry distribution chart, Dermapharm Holding SE ranks #188 out of 558 companies in the Drug Manufacturers industry, placing it in the top 33.7%.
Is Dermapharm Holding SE's EV-to-FCF too high?
Dermapharm Holding SE's current EV-to-FCF of 12.84 is 22% below median its 10-year median of 16.51. Over the past 10 years, this metric has ranged from a low of 6.17 to a high of 139.75. The Drug Manufacturers industry median EV-to-FCF is 20.05. Dermapharm Holding SE's value of 12.84 is 35.9% below this industry median. Based on the distribution chart, Dermapharm Holding SE ranks #188 out of 558 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Dermapharm Holding SE has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dermapharm Holding SE ranks #188 out of 558 companies for EV-to-FCF. This puts Dermapharm Holding SE in the upper half of its industry. The industry median EV-to-FCF is 20.05. Dermapharm Holding SE's value of 12.84 is 35.9% below this benchmark. Historically, Dermapharm Holding SE's own EV-to-FCF has ranged from 6.17 to 139.75 over the past decade. While the company's 10-year median is 16.51 vs. the industry median of 20.05, Dermapharm Holding SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.05, based on 558 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dermapharm Holding SE's current EV-to-FCF of 12.84 is 35.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Dermapharm Holding SE and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermapharm Holding SE's current EV-to-FCF is 12.84, which is 22% below median its own 10-year median of 16.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Based on GuruFocus' analysis, Dermapharm Holding SE (DMPHF) is currently considered Modestly Overvalued. The stock's GF Value™ is $44.29, compared to a current price of $53.00 — trading 19.7% above its estimated fair value. The current EV-to-FCF is 12.84, which is 22% below median its 10-year median of 16.51 and 35.9% below the Drug Manufacturers industry median of 20.05. Dermapharm Holding SE's overall GF Score™ is 83/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Dermapharm Holding SE (DMPHF), the current EV-to-FCF is 12.84 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dermapharm Holding SE (DMPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued.
The current stock price of $53.00 is trading 19.7% above its estimated GF Value™ of $44.29.
GuruFocus considers Dermapharm Holding SE to be Modestly Overvalued.
Key valuation signals for DMPHF:
EV-to-FCF: 12.84 (22% below median its 10-year median of 16.51)
GF Value™: $44.29 vs. price of $53.00 (19.7% above fair value)
Industry Position: 35.9% below the Drug Manufacturers median (#188 of 558)
No single metric tells the full story. See the DMPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
83GF Score
Get the complete analysis for DMPHF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMPHF has been successfully added to your 
